Opinion: dealing with failure, iTeos style
When your investment case breaks down, why not just do the decent thing?
Nuvation gets in before Nuvalent
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
ASCO 2025 – Astra "looked at" patritumab but passed
As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.
Uncontrolled trial strategy sinks UroGen
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
Asia stymies Columvi's expansion
Starglo isn't applicable to a US population, an adcom rules.
